- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Viela Bio is a biotechnology business based in the US. Viela Bio shares (VIE) are listed on the NASDAQ and all prices are listed in US Dollars. Viela Bio employs 170 staff and has a trailing 12-month revenue of around $11.7 million.
Our top picks for where to buy Viela Bio stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Viela Bio stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VIE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Viela Bio stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Viela Bio stock price (NASDAQ: VIE)
Use our graph to track the performance of VIE stocks over time.Viela Bio shares at a glance
Information last updated 2023-12-12.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $53.07 |
| 200-day moving average | $39.12 |
| Wall St. target price | $53.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-78.90 |
Is it a good time to buy Viela Bio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Viela Bio financials
| Revenue TTM | $11.7 million |
|---|---|
| Gross profit TTM | $9.6 million |
| Return on assets TTM | -23.83% |
| Return on equity TTM | -41.26% |
| Profit margin | 0% |
| Book value | $-293.22 |
| Market Capitalization | $2.9 billion |
TTM: trailing 12 months
Viela Bio share dividends
We're not expecting Viela Bio to pay a dividend over the next 12 months.
Viela Bio overview
Viela Bio, Inc. , a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; and which is in Phase III trials for patients with myasthenia gravis and IgG4-related diseases, as well as in Phase II trial for kidney transplant desensitization. It is also developing VIB4920 that is in Phase II trial for kidney transplantation rejection and rheumatoid arthritis, as well as in Phase IIb trial for sjögren's syndrome; and VIB7734, which is in Phase Ib trial for cutaneous lupus erythematosus, in Phase I trial for COVID-19-related acute lung injury, and a planned Phase II tria for systemic lupus erythematosus. The company's pre-clinical research and development product candidates include VIB1116 to decrease the number and function of antigen-presenting dendritic cells; and a mAb cytokine fusion protein to inhibit inflammatory responses. Viela Bio, Inc. has a strategic collaboration with Hansoh Pharmaceutical Group Company Limited and Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in China, Hong Kong, Macau, Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan.
Frequently asked questions
What percentage of Viela Bio is owned by insiders or institutions?Currently 55.079% of Viela Bio shares are held by insiders and 47.165% by institutions. How many people work for Viela Bio?
Latest data suggests 170 work at Viela Bio. When does the fiscal year end for Viela Bio?
Viela Bio's fiscal year ends in December. Where is Viela Bio based?
Viela Bio's address is: One MedImmune Way, Gaithersburg, MD, United States, 20878 What is Viela Bio's ISIN number?
Viela Bio's international securities identification number is: US9266131005 What is Viela Bio's CUSIP number?
Viela Bio's Committee on Uniform Securities Identification Procedures number is: 926613100
More resources on Finder
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question